{"id":"W4391786157","doi":"10.1007/s00262-023-03623-z","title":"INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors","year":2024,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"MacroGenics; AstraZeneca; Eli Lilly and Company; Astellas Pharma; Bristol-Myers Squibb","keywords":"Tremelimumab; Medicine; Tolerability; Discontinuation; Adverse effect; Oncology; Internal medicine; Response Evaluation Criteria in Solid Tumors; Cancer; Phases of clinical research; Clinical trial; Immunotherapy; Ipilimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002020136,0.002066872,0.002038965,0.000663488,0.0004923365,0.000996406,0.0008219833,0.001280073,0.004571945],"category_scores_gemma":[0.0008046823,0.0007686979,0.00122941,0.0003995925,0.0008585553,0.001140019,0.0004398943,0.002935549,0.001041573],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000915835,"about_ca_system_score_gemma":0.001654671,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005176446,"about_ca_topic_score_gemma":0.001440219,"domain_scores_codex":[0.9995059,0.0002397788,0.00002332814,0.00007252078,0.00005312087,0.0001053574],"domain_scores_gemma":[0.9995111,0.00006982964,0.0001052773,0.00005089505,0.00003501053,0.000227788],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5875503,0.2330035,0.004957959,0.001218912,0.0009323359,0.0003672644,0.0004061933,0.002959406,0.0835363,0.000466564,0.003857952,0.08074334],"study_design_scores_gemma":[0.458383,0.5264146,0.005632642,0.00002231646,0.0002365589,0.000234088,0.00004708571,0.0008845322,0.005059732,0.0001480498,0.002909309,0.00002808454],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866215,0.001349051,0.0009538771,0.0004518997,0.00013293,0.007363129,0.001387426,0.0001367234,0.001603422],"genre_scores_gemma":[0.9754995,0.001677725,0.003967202,0.001240882,0.0003661485,0.009512063,0.002541004,0.00006232451,0.005133081],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004571945,"threshold_uncertainty_score":0.01529467,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02397063968778328,"score_gpt":0.3438805567695655,"score_spread":0.3199099170817822,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}